# GD2 CAR-T as consolidation in high-risk neuroblastoma

Source: https://onco.cc/ideas/idea-gd2-car-t-frontline-consolidation/  
OnCo record `idea-gd2-car-t-frontline-consolidation` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Give engineered GD2 T cells to children in remission after standard therapy, where the long-term data show the deepest and longest cures.

## Summary

This idea would give GD2-directed CAR-T cells to children with high-risk neuroblastoma who are in remission after induction, surgery and transplant, replacing or following tandem transplant and anti-GD2 antibody therapy. Long-term follow-up of the GD2-CART01 phase 1/2 trial at Bambino Gesù showed that most children infused with no evidence of disease have remained disease-free for many years, far better than expected with standard therapy. The rationale is that minimal residual disease is the ideal setting for CAR-T, that GD2 is retained after chemotherapy, and that a safety switch mitigates risk. The proposed test is a randomised phase 2/3 within COG or SIOPEN; at an early clinical stage, it addresses the bottleneck of rare and paediatric cancers and sits in the paediatric roadmap.

## Fields

- Kind: Idea
- Last checked: 2026-09-07
- Hypothesis: GD2 CAR-T consolidation after induction, surgery and transplant improves 3-year EFS from ~60% to ≥75% in high-risk neuroblastoma with acceptable CRS and no chronic neuropathy.
- Rationale: Minimal residual disease is the ideal CAR-T setting; GD2 is retained after chemotherapy; safety switch mitigates risk.
- Proposed test: Randomised phase 2/3 within COG or SIOPEN: standard anti-GD2 immunotherapy vs anti-GD2 followed by GD2 CAR-T; EFS primary.
- Maturity: early-clinical

## Sources

- ClinicalTrials.gov NCT03373097: GD2-CART01 (Bambino Gesù phase 1/2): https://clinicaltrials.gov/study/NCT03373097

## Connected records

- cancers: [High-risk neuroblastoma](https://onco.cc/cancers/neuroblastoma-high-risk/), [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/)
- technologies: [Armoured, logic-gated & next-gen CARs](https://onco.cc/technologies/armored-car/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [GD2 (disialoganglioside)](https://onco.cc/targets/gd2/)
- trials: [GD2-CART01 (Bambino Gesù phase 1/2)](https://onco.cc/trials/gd2-cart01/)
- bottlenecks: [Rare and paediatric cancers without markets](https://onco.cc/bottlenecks/b-rare-cancers/)
- roadmaps: [Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first](https://onco.cc/roadmaps/paediatric-oncology-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/idea-gd2-car-t-frontline-consolidation.json